Abstract Library

#4667 Clinical outcomes in patients with typical (TC) and atypical bronchial carcinoids (AC): A 15-year retrospective study from an ENETS Center of Excellence

Introduction: Bronchial neuroendocrine neoplasms (NENs) can be subdivided into TCs, ACs and neuroendocrine carcinomas (NECs). Although a few studies have explored treatment approaches and oncological outcomes, most focus on surgical cohorts, small sample sizes, or mixed groups including TC, AC, and NECs. Real-life cohort data are lacking.

Conference:

Presenting Author: Clement D

Authors: Correia J, Sarker D, Dolly S, Frydman A, Srirajaskanthan R,

Keywords: bronchial carcinoid, treatment pattern, recurrence-free survival, overall survival,

#4663 CAREFNDR: A phase III, randomised, parallel group, placebo-controlled study to evaluate the efficacy and safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumours

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for carcinoid syndrome (CS) treatment. In a Phase 2, open-label, dose-ranging study, paltusotine reduced the frequency and severity of CS symptoms and was well tolerated (NCT05361668).

Conference:

Presenting Author:

Authors: Kim R, Usiskin K, Fan X, Quock T, Mui C,

Keywords: paltusotine, phase 3 trial, somatostatin receptor agonist, neuroendocrine tumour, carcinoid syndrome,

#4643 Characterisation of patients with progressive digestive NET during PRRT (LUTA-CHEC): A multicentre study from the Groupe des Tumeurs Endocrines

Introduction: PRRT with 177Lu-DOTATATE is a major treatment for metastatic digestive NETs. Most patients have prolonged progression-free survival, but around 20% experience early progression.

Conference:

Presenting Author: Haissaguerre M

Authors: Haissaguerre M, Hadoux J, Tlili G, Deshayes E, Lacombe M,

Keywords: GEP-NET, PRRT, early tumour progression,

#4634 Management of hypercalcaemia of malignancy in neuroendocrine tumour patients – A case series

Introduction: Hypercalcaemia of malignancy (HM) rarely coexists with neuroendocrine tumours (NET). There are no precise guidelines for management of hypercalcaemia in NET.

Conference:

Presenting Author:

Authors: Klepinowska M, Sagan K, Brzeska A, Andrysiak-Mamos E, Kiedrowicz B,

Keywords: hypercalcaemia of malignancy, neuroendocrine tumour, pancreatic neuroendocrine tumour, hypercalcaemia,

#4633 Mini invasive pancreatectomy for pancreatic neuroendocrine tumours: Current state of management in France

Introduction: Pancreatic neuroendocrine tumours (NETs) accounts for 2% of pancreatic tumours and their management is challenging. Surgery is the most radical treatment, but for small lesions, parenchyma sparing techniques are also used.

Conference:

Presenting Author: Muzzolini M

Authors: Muzzolini M, de Ponthaud C, Gaujoux S,

Keywords: laparoscopic NETs surgical outcomes,